Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Chandrima Sanyal

Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For

Two irregular red cells

Moderna Inc.’s (NASDAQ:MRNA) latest cancer-vaccine breakthrough could be doing more than sending its stock sharply higher. It may be giving investors a reason to revisit an mRNA investment thesis that has largely been defined by COVID-19. ETFs tied to precision medicine names are also getting a boost.

• Moderna stock is at critical resistance. Why are MRNA shares at highs?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.